PDCD1 and hepatocellular carcinoma: In HCC patients, generally known for better anti-PD-1 treatment response rates of 15-20% (4, 27), we found a higher frequency of partially exhausted TRM cells, expressing not only elevated levels of PD-1, but also TIGIT, Tim-3, and the co-stimulatory checkpoint ICOS.